Hosted on MSN1mon
Chinese regulators accept Zai Lab application for KarXT
Chinese regulators have accepted Zai Lab's (NASDAQ:ZLAB) market application for the drug KarXT, also known as xanomeline and trospium chloride, for the treatment of schizophrenia in adults.
pharmaphorum1y
BMS wagers $14bn on Karuna’s schizophrenia drug
Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion.
pharmaphorum1y
FDA kicks off review of Karuna’s schizophrenia drug KarXT
GlobalData has predicted that KarXT will launch in the US next year, and achieve sales of $1.1 billion by 2031 thanks to its safety profile and ability to broadly target symptoms of schizophrenia ...
Business Wire1mon
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
“KarXT is the first new class of treatment for ... as compared to current antipsychotic medicines, which mostly target dopamine or serotonin receptors. Zai Lab has an exclusive license from ...
Business Insider1mon
Zai Lab announces China’s NMPA accepted NDA for KarXT
Zai Lab (ZLAB) announced that China’s National Medical Products Administration, NMPA, has accepted the New Drug Application, NDA, for KarXT for the treatment of schizophrenia in adults.